{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:31:03Z","timestamp":1793741463912,"version":"4.6.1"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"11-12","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The conflict in Ukraine highlights the significant challenges posed by antimicrobial resistance (AMR) in resource-limited and combat settings. Alarming rates of multidrug-resistant organisms, including carbapenem-resistant organisms causing up to 60% of healthcare-associated infections, have been reported from Ukrainian hospitals during the conflict. This narrative review examines the current landscape and potential application of diagnostic testing and antimicrobial treatments for high-priority MDROs relevant to these settings, specifically carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Acinetobacter baumannii complex, and carbapenem-resistant Pseudomonas aeruginosa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This narrative review synthesized information from relevant scientific literature and expert knowledge concerning AMR diagnostics and therapeutics. The focus was on evaluating the application and limitations of current and novel strategies for managing CRE, carbapenem-resistant A. baumannii complex, and carbapenem-resistant P. aeruginosa in resource-limited and combat environments, using the ongoing conflict in Ukraine as a key contextual example. We did not employ a systematic literature search protocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Diagnostic capabilities in resource-limited settings are often constrained, limiting effective AMR surveillance and targeted therapy. Traditional culture and basic antimicrobial susceptibility testing (AST) face challenges; adaptations like direct disk diffusion and deployable molecular tests offer enhanced capability closer to the field. Newer diagnostics like MALDI-TOF and NGS show promise, but face implementation hurdles related to cost, infrastructure, and interpretation. Treatment in resource-limited and combat settings, such as during the conflict in Ukraine, is severely constrained by a complex intersection of logistical and clinical barriers. These obstacles include a lack of regional epidemiology data, as well as significant supply chain issues involving cold chain requirements, drug instability, and the need for sterile compounding. Furthermore, the administration of novel agents against carbapenem-resistant pathogens is often impractical in austere environments due to the necessity for frequent dosing, prolonged infusion times, and reliable intravenous access. The ongoing development of ultra-broad-spectrum oral agents represents a vital advancement that may facilitate rapid treatment initiation far-forward without the burden of cold-chain logistics or complex IV equipment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AMR presents a critical threat in conflict and resource-limited settings, exacerbated by challenges in diagnostics and treatment logistics. Although novel diagnostic technologies and antimicrobial agents provide potential solutions for managing infections caused by resistant organisms, significant barriers to their effective implementation exist. Addressing these obstacles requires targeted research and adaptation of strategies to ensure optimal deployment of diagnostics and therapeutics in austere environments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/milmed\/usag024","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:33:45Z","timestamp":1768566825000},"page":"e2305-e2313","source":"Crossref","is-referenced-by-count":2,"title":["The Evolving Frontline of Antimicrobial Resistance: Adapting Testing and Treatment for Austere and Combat Settings"],"prefix":"10.1093","volume":"191","author":[{"given":"Kyle C","family":"Molina","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine, University of Colorado School of Medicine , Aurora, CO 80045,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Bills","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, University of Colorado School of Medicine , Aurora, CO 80045,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8816-1199","authenticated-orcid":false,"given":"Vikhyat S","family":"Bebarta","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, University of Colorado School of Medicine , Aurora, CO 80045,","place":["United States"]},{"name":"Center for Combat Medicine and Battlefield Research, School of Medicine, University of Colorado Anschutz Medical Campus , Aurora, CO 80045,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Fishchuk","sequence":"additional","affiliation":[{"name":"Central City Clinical Hospital of Ivano-Frankivsk City Council Clinical Trials Department, , Ivano-Frankivsk, 76000,","place":["Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W","family":"Mueller","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Colorado Hospital , Aurora, CO 80045,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L","family":"Peers","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, University of Colorado School of Medicine , Aurora, CO 80045,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, University of Colorado School of Medicine , Aurora, CO 80045,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy A","family":"Trent","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, University of Colorado School of Medicine , Aurora, CO 80045,","place":["United States"]},{"name":"Department of Emergency Medicine, Denver Health Medical Center , Denver, CO 80204,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adit A","family":"Ginde","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, University of Colorado School of Medicine , Aurora, CO 80045,","place":["United States"]},{"name":"Center for Combat Medicine and Battlefield Research, School of Medicine, University of Colorado Anschutz Medical Campus , Aurora, CO 80045,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"2026110316200675100_usag024-B1","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/antibiotics9090579","article-title":"Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii isolated from war-injured patients from the Eastern Ukraine","volume":"9","author":"Higgins","year":"2020","journal-title":"Antibiotics"},{"key":"2026110316200675100_usag024-B2","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.15585\/mmwr.mm7249a5","article-title":"Notes from the field: responding to the wartime spread of antimicrobial-resistant organisms\u2013Ukraine, 2022","volume":"72","author":"Kuzin","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026110316200675100_usag024-B3","doi-asserted-by":"publisher","first-page":"2200926","DOI":"10.2807\/1560-7917.ES.2022.27.50.2200926","article-title":"Increase in NDM-1 and NDM-1\/OXA-48-producing Klebsiella pneumoniae in Germany associated with the war in Ukraine, 2022","volume":"27","author":"Sandfort","year":"2022","journal-title":"Euro Surveill"},{"key":"2026110316200675100_usag024-B4","article-title":"Tackling drug-resistant infections globally: final report and recommendations","author":"O\u2019Neill","year":"2016"},{"key":"2026110316200675100_usag024-B5","article-title":"Government review says antibiotics should not be prescribed without rapid diagnostic test","volume":"296","author":"Torjesen","year":"2016","journal-title":"Pharm J"},{"key":"2026110316200675100_usag024-B6","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3389\/fmicb.2015.00791","article-title":"MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis","volume":"6","author":"Singhal","year":"2015","journal-title":"Front Microbiol"},{"key":"2026110316200675100_usag024-B7","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001571","article-title":"Identification of micro-organism from positive blood cultures: comparison of three different short culturing methods to the rapid sepsityper workflow","volume":"71","author":"Pranada","year":"2022","journal-title":"J Med Microbiol"},{"key":"2026110316200675100_usag024-B8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/jof7030178","article-title":"T2Candida for the diagnosis and management of invasive candida infections","volume":"7","author":"Monday","year":"2021","journal-title":"J Fungi"},{"key":"2026110316200675100_usag024-B9","article-title":"How next-generation sequencing can address the antimicrobial resistance challenge","author":"Rupp\u00e9","year":"2016"},{"key":"2026110316200675100_usag024-B10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.tig.2014.07.003","article-title":"Whole-genome sequencing to control antimicrobial resistance","volume":"30","author":"K\u00f6ser","year":"2014","journal-title":"Trends Genet"},{"key":"2026110316200675100_usag024-B11","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/genes9050268","article-title":"The present and future of whole genome sequencing (WGS) and whole metagenome sequencing (WMS) for surveillance of antimicrobial resistant microorganisms and antimicrobial resistance genes across the food chain","volume":"9","author":"Oniciuc","year":"2018","journal-title":"Genes"},{"key":"2026110316200675100_usag024-B12","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/S0140-6736(18)30459-8","article-title":"Improving pathology and laboratory medicine in low-income and middle-income countries: roadmap to solutions","volume":"391","author":"Sayed","year":"2018","journal-title":"Lancet"},{"key":"2026110316200675100_usag024-B13","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/S0140-6736(21)00673-5","article-title":"The lancet commission on diagnostics: transforming access to diagnostics","volume":"398","author":"Fleming","year":"2021","journal-title":"Lancet"},{"key":"2026110316200675100_usag024-B14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"2026110316200675100_usag024-B15","doi-asserted-by":"publisher","first-page":"e0000710","DOI":"10.1371\/journal.pgph.0000710","article-title":"Diagnostic tests to mitigate the antimicrobial resistance pandemic\u2014still the problem child","volume":"2","author":"Ferreyra","year":"2022","journal-title":"PLOS Glob Public Health"},{"key":"2026110316200675100_usag024-B16","doi-asserted-by":"publisher","first-page":"e01990-21","DOI":"10.1128\/AAC.01990-21","article-title":"In vitro susceptibility of gram-negative pathogens to cefiderocol in five consecutive annual multinational SIDERO-WT surveillance studies, 2014 to 2019","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026110316200675100_usag024-B17","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026110316200675100_usag024-B18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026110316200675100_usag024-B19","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026110316200675100_usag024-B20","doi-asserted-by":"publisher","first-page":"709974","DOI":"10.3389\/fmicb.2021.709974","article-title":"Durlobactam, a new diazabicyclooctane \u03b2-lactamase inhibitor for the treatment of Acinetobacter infections in combination with sulbactam","volume":"12","author":"Shapiro","year":"2021","journal-title":"Front Microbiol"},{"key":"2026110316200675100_usag024-B21","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/phar.2802","article-title":"Sulbactam-durlobactam: a novel \u03b2-lactam-\u03b2-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections","volume":"43","author":"El-Ghali","year":"2023","journal-title":"Pharmacotherapy"},{"key":"2026110316200675100_usag024-B22","doi-asserted-by":"publisher","first-page":"17104","DOI":"10.1038\/nmicrobiol.2017.104","article-title":"ETX2514 is a broad-spectrum \u03b2-lactamase inhibitor for the treatment of drug-resistant gram-negative bacteria including Acinetobacter baumannii","volume":"2","author":"Durand-R\u00e9ville","year":"2017","journal-title":"Nat Microbiol"},{"key":"2026110316200675100_usag024-B23","doi-asserted-by":"publisher","first-page":"e00781-22","DOI":"10.1128\/aac.00781-22","article-title":"In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii-calcoaceticus complex collected from 2016 to 2021","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026110316200675100_usag024-B24","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam\u2013durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii\u2013calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026110316200675100_usag024-B25","doi-asserted-by":"publisher","first-page":"e00105-19","DOI":"10.1128\/AAC.00105-19","article-title":"Beyond piperacillin-tazobactam: cefepime and AAI101 as a potent \u03b2-lactam\u2212\u03b2-lactamase inhibitor combination","volume":"63","author":"Papp-Wallace","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026110316200675100_usag024-B26","doi-asserted-by":"publisher","first-page":"e00514-19","DOI":"10.1128\/AAC.00514-19","article-title":"In vitro activity of cefepime-enmetazobactam against gram-negative isolates collected from U.S. and European hospitals during 2014\u20132015","volume":"63","author":"Morrissey","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026110316200675100_usag024-B27","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of cefepime\/enmetazobactam vs piperacillin\/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"key":"2026110316200675100_usag024-B28","doi-asserted-by":"publisher","first-page":"ofad046","DOI":"10.1093\/ofid\/ofad046","article-title":"Changing epidemiology of carbapenemases among carbapenem-resistant Enterobacterales from United States hospitals and the activity of aztreonam-avibactam against contemporary enterobacterales (2019\u20132021)","volume":"10","author":"Sader","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026110316200675100_usag024-B29","author":"Phase 3 Studies of Pfizer\u2019s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options | Pfizer"},{"key":"2026110316200675100_usag024-B30","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-\u03b2-lactamase-Producing enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026110316200675100_usag024-B31","doi-asserted-by":"publisher","first-page":"e01963","DOI":"10.1128\/AAC.01963-19","article-title":"VNRX-5133 (taniborbactam), a broad-spectrum inhibitor of serine- and metallo-\u03b2-lactamases, restores activity of cefepime in enterobacterales and Pseudomonas aeruginosa","volume":"64","author":"Hamrick","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026110316200675100_usag024-B32","doi-asserted-by":"publisher","first-page":"8544","DOI":"10.1021\/acs.jmedchem.9b00911","article-title":"Bicyclic boronate VNRX-5133 inhibits metallo- and serine-\u03b2-lactamases","volume":"62","author":"Krajnc","year":"2019","journal-title":"J Med Chem"},{"key":"2026110316200675100_usag024-B33","doi-asserted-by":"publisher","first-page":"e01281-22","DOI":"10.1128\/aac.01281-22","article-title":"In vitro activity of cefepime-taniborbactam and comparators against clinical isolates of gram-negative bacilli from 2018 to 2020: results from the global evaluation of antimicrobial resistance via surveillance (GEARS) program","volume":"67","author":"Karlowsky","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026110316200675100_usag024-B34","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1093\/jac\/dkae329","article-title":"Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018-22","volume":"79","author":"Karlowsky","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026110316200675100_usag024-B35","doi-asserted-by":"publisher","first-page":"e04925\u201322","DOI":"10.1128\/spectrum.04925-22","article-title":"In vitro activity of two cefepime-based novel combinations, cefepime\/taniborbactam and cefepime\/zidebactam, against carbapenemase-expressing Enterobacterales collected in India. Papp-Wallace KM, ed","volume":"11","author":"Bakthavatchalam","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2026110316200675100_usag024-B36","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa2304748","article-title":"Cefepime\u2013taniborbactam in complicated urinary tract infection","volume":"390","author":"Wagenlehner Florian","year":"2024","journal-title":"N Engl J Med"},{"key":"2026110316200675100_usag024-B37","doi-asserted-by":"publisher","first-page":"e00072","DOI":"10.1128\/AAC.00072-17","article-title":"WCK 5222 (cefepime-zidebactam) antimicrobial activity against clinical isolates of gram-negative bacteria collected worldwide in 2015","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026110316200675100_usag024-B38","doi-asserted-by":"publisher","first-page":"e01432","DOI":"10.1128\/AAC.01432-20","article-title":"In vitro activity of WCK 5222 (cefepime-zidebactam) against worldwide collected gram-negative bacilli not susceptible to carbapenems","volume":"64","author":"Karlowsky","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026110316200675100_usag024-B39","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1093\/jac\/dkac233","article-title":"Antimicrobial activity of cefepime\/zidebactam (WCK 5222), a \u03b2-lactam\/\u03b2-lactam enhancer combination, against clinical isolates of gram-negative bacteria collected worldwide (2018\u201319)","volume":"77","author":"Sader","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026110316200675100_usag024-B40","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/jac\/dkab067","article-title":"Activity of cefepime\/zidebactam (WCK 5222) against \u201cproblem\u201d antibiotic-resistant gram-negative bacteria sent to a national reference laboratory","volume":"76","author":"Mushtaq","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026110316200675100_usag024-B41","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12941-023-00606-x","article-title":"Compassionate use of a novel \u03b2-lactam enhancer-based investigational antibiotic cefepime\/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report","volume":"22","author":"Dubey","year":"2023","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2026110316200675100_usag024-B42","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01346-22","article-title":"In Vitro Activity of Ceftibuten-Avibactam against \u03b2-Lactamase-Positive Enterobacterales from the ATLAS Global Surveillance Program","volume":"67","author":"Karlowsky","journal-title":"Antimicrob Agents Chemother"},{"key":"2026110316200675100_usag024-B43","doi-asserted-by":"publisher","first-page":"e00440","DOI":"10.1128\/aac.00440-23","article-title":"In vitro potency of xeruborbactam in combination with multiple \u03b2-lactam antibiotics in comparison with other \u03b2-lactam\/\u03b2-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum \u03b2-lactamase-producing Enterobacterales","volume":"67","author":"Lomovskaya","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026110316200675100_usag024-B44","doi-asserted-by":"publisher","first-page":"e0087922","DOI":"10.1128\/aac.00879-22","article-title":"Intrinsic Antibacterial Activity of Xeruborbactam In Vitro: Assessing Spectrum and Mode of Action","volume":"66","author":"Sun","year":"2022","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/191\/11-12\/e2305\/67315984\/usag024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/milmed\/article-pdf\/191\/11-12\/e2305\/67315984\/usag024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:20:15Z","timestamp":1793740815000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/191\/11-12\/e2305\/8516322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":44,"journal-issue":{"issue":"11-12","published-online":{"date-parts":[[2026,3,12]]},"published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usag024","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,3,12]]}}}